SR3335，5MG，SML2820-5MG，Sigma

Biochem/physiol Actions

SR3335 is a selective partial inverse agonist against the retinoic acid receptor-related orphan receptor ROR-alpha (RORα LBD K_i = 220 nM) that selectively inhibits the constitutive transactivation activity of RORα (IC₅₀ = 480 nM), but not RORβ, RORγ or LXRα, by cell-based reporter assays without affinity toward other RORs. SR3335 effectively suppresses HepG2 cellular RORα target genes expression (5 μM) and improves pyruvate tolerance in DIO mice in vivo (15 mg/kg bid. Ip.) by suppressing gluconeogenesis.
Selective retinoic acid receptor-related receptor RORα partial inverse agonist that improves pyruvate tolerance in DIO mice in vivo.